Literature DB >> 32589479

LncRNA TUG1 Promotes Hepatocellular Carcinoma Migration and Invasion Via Targeting the miR-137/AKT2 Axis.

Wei Li1, Jinzhao Ge2, Jinju Xie1, Jidong Yang1, Jin'e Chen1, Tao He3.   

Abstract

Background: The current study aimed to investigate the effects of TUG1 on the migration and invasion of hepatoma cells. Materials and
Methods: The expressions of TUG1, miR-137, and AKT2 were detected in hepatoma tissues and cells by performing quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The correlations among TUG1, miR-137, and AKT2 were predicted by bioinformatics analysis and confirmed by dual-luciferase reporter assay, and Pearson test was performed to analyze their relevance. The effects of TUG1, miR-137, and AKT2 on viability, migration, and invasion of transfected hepatoma cells were detected by CCK-8, wound scratch, and Transwell. Epithelial-mesenchymal transition (EMT)-related protein levels were determined by Western blot and qRT-PCR.
Results: TUG1 was highly expressed in hepatoma tissues and cells. Silencing TUG1 expression inhibited the viability, migration, and invasion of hepatoma cells. TUG1 targeted miR-137 and the two was negatively correlated, and silencing TUG1 expression inhibited the effects of low-expressed miR-137 on promoting proliferation, migration, and invasion of hepatoma cells. AKT2 was predicted to be the target gene for miR-137, and the two were negatively correlated. Moreover, inhibiting miR-137 expression promoted the expression of MMP2, MMP9, and N-cadherin and inhibited E-cadherin expression, while silencing TUG1 expression reversed the effects of low-expressed miR-137 on EMT-related protein levels.
Conclusion: LncRNA TUG1 promotes hepatocellular carcinoma migration and invasion through targeting the miR-137/AKT2 axis.

Entities:  

Keywords:  AKT2; LncRNA TUG1; hepatocellular carcinoma; invasion; miR-137; migration

Mesh:

Substances:

Year:  2020        PMID: 32589479     DOI: 10.1089/cbr.2019.3297

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  5 in total

1.  Circular RNA circPVT1 Contributes to Doxorubicin (DXR) Resistance of Osteosarcoma Cells by Regulating TRIAP1 via miR-137.

Authors:  Dan Li; Yan Huang; Gang Wang
Journal:  Biomed Res Int       Date:  2021-04-23       Impact factor: 3.411

Review 2.  Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.

Authors:  Mohamed H Yousef; Hassan A N El-Fawal; Anwar Abdelnaser
Journal:  Biomed Res Int       Date:  2020-11-24       Impact factor: 3.411

3.  Long Noncoding RNA TUG1 Inhibits Tumor Progression through Regulating Siglec-15-Related Anti-Immune Activity in Hepatocellular Carcinoma.

Authors:  Yanyi Ren; Jiayi Lyu; Yaoguang Guo; Yuan Yao; Lin Hu
Journal:  J Immunol Res       Date:  2022-02-21       Impact factor: 4.818

4.  LncRNA ZNF674-AS1 Hinders Proliferation and Invasion of Hepatic Carcinoma Cells through the Glycolysis Pathway.

Authors:  Dongliang Li; Yan Xie; Jisan Sun; Li Zhang; Wentao Jiang
Journal:  J Oncol       Date:  2022-07-13       Impact factor: 4.501

5.  LncRNA-TUG1 promotes the progression of infantile hemangioma by regulating miR-137/IGFBP5 axis.

Authors:  Lili Zhou; Xiao Jia; Xiangzheng Yang
Journal:  Hum Genomics       Date:  2021-08-06       Impact factor: 4.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.